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Abstract
Background: Acquired brain injury (ABI) affects approximately 79.3 million individuals annually and is linked with
elevated rates of depression and low mood. Existing methods for treating depression in ABI have shown mixed
efficacy. Behavioural activation (BA) is a potentially promising intervention. Its premise is that individuals with low
mood avoid planning and engaging in activities due to low expectations of a positive outcome. Consequently, their
exposure to positive reinforcement is reduced, exacerbating low mood. BA aims to break this cycle by encouraging
activity planning and engagement. It is unknown whether cognitive demands of traditional BA may undermine
efficacy in ABI. Here, we assess the feasibility and acceptability of two groups designed to increase activity
engagement. In the activity planning group (traditional BA), the importance of meaningful and positive activity will be
discussed and participants encouraged to plan/engage in activities in everyday life. The activity engagement group
(experiential BA) instead focuses on engagement in positive experiences (crafts, games, discussion) within the group.
The primary aims are to evaluate the feasibility and acceptability of the two groups in ABI. A secondary aim is to
explore relative efficacy of the groups compared to an equivalent period of waitlist controls.
Method: This study outlines a parallel-arm pilot feasibility trial for individuals with low mood and ABI that compares a
traditional vs experiential BA group vs waitlist controls. Adults (≥ 18 years) will be recruited from local ABI services and
randomised to condition. Feasibility and acceptability will be assessed via recruitment, retention, attendance and
participant feedback. Groups will be compared (pre- and post-intervention and 1month follow-up) by assessing self-
reported activity engagement. Secondary outcomes include self-report measures of depression, anxiety, post-traumatic
distress related to the ABI, motivation, participation and sense of control over one’s life.
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Background
Acquired brain injury (ABI) refers to damage to the
brain from a blow to the head (traumatic brain injury;
TBI), from an interruption to the brain’s blood supply
(stroke) or oxygen supply (anoxia), or as a result of pres-
sure from a growing tumour [1]. In the United Kingdom
(UK), TBI’s affect 531 per 100,000 individuals per year
[2] and stroke approximately 115 per 100,000 individuals
[3]. Anoxic brain damage due to cardiac arrest affects
roughly 50 people per 100,000 annually [4], brain tu-
mours a further 7 per 100,000 [5] and encephalitis ap-
proximately 5 per 100,000 per year [6]. The cost of just
TBI and stroke in the UK is £15 billion and £8.9 billion
per year, respectively [7, 8]. Taken together, ABI is a
leading cause of long-term disability worldwide [9] and
presents a considerable public health challenge.
ABIs can have far-reaching negative effects on an indi-
vidual’s physical, cognitive, behavioural, emotional and so-
cial status [2, 10]. The purpose of rehabilitation is to
enable those with an ABI to successfully reintegrate into
the community by developing essential skills necessary for
a patient’s goals [11]. However, positive long-term out-
come of rehabilitation can be significantly reduced by de-
pression [12, 13]. In the UK, approximately half of all
people with an ABI—354 of the estimated 708 individuals
per 100,000—will experience depression in the first year
after their injury, of those with ABI with depression,
roughly 66% do not fully recover from their depressive
symptoms [14]. Individuals with an ABI and depression
are more likely to experience greater difficulties in many
aspects of day-to-day function [8, 9], including poorer
quality of life, impaired overall cognitive function, reduced
physical activity and engagement in activities of daily liv-
ing and a higher mortality rate [15–18]. Alarmingly, indi-
viduals with an ABI are at least 3 times as likely to die by
suicide relative to the general population [19].
Clearly, there is an urgent need to develop effective in-
terventions for depression in ABI populations. Though
existing therapies for depression such as cognitive be-
havioural therapy (CBT) have a strong evidence base in
the general population, they place heavy demands on
skills often compromised in ABI, such as comprehen-
sion, memory and mental flexibility, which may help ac-
count for the mixed outcomes for CBT in ABI [20]. A
promising alternative with lower demands and
established efficacy in the non-ABI population is behav-
ioural activation (BA). Individuals with depression have
difficulties anticipating and imagining positive future ac-
tivities and tend not to plan or engage in them [21–23]
for reasons that include reduced motivation, fatigue, or
fear of negative consequences. This limits their exposure
to opportunities for positive reinforcement which can
exacerbate low mood [24]. In BA, rather than waiting
until their mood improves spontaneously, individuals are
encouraged to plan and engage in meaningful and val-
ued activities and overcome barriers to their occurrence.
Despite its simplicity, BA’s effectiveness in the non-ABI
population is on par with medication and CBT, with a
pooled effect size of 0.78 between BA and control condi-
tions [25–27]. Since BA has relatively low cognitive de-
mands compared with, say, CBT, it may be particularly
well suited to individuals with ABI. Furthermore, a core
component of BA is problem-solving barriers related to
activity engagement, which is well suited to addressing
the considerable cognitive, physical, motivational and so-
cietal challenges that are common in ABI. Reduced ac-
tivity engagement is an important factor contributing to
the elevated rates of depression and low mood in ABI
[28–32] and thus interventions aimed at improving ac-
tivity engagement are well suited toward this population.
Promising work examining BA in the specific context of
stroke is already underway [33, 34]. In a re-analysis of
randomised controlled trial data, Bombardier et al. [35]
concluded that environmental rewards from daily activ-
ities correlated with decreased depression, suggesting
the BA-style interventions may be appropriate in TBI as
well. This is the first trial of which we are aware to ex-
plore BA with respect to the wider ABI population and
to do so using group rather than individual approaches.
An important issue given the mixed efficacy of other
psychological interventions for mood in ABI is whether
the cognitive demands of BA, although notably lower
than other approaches, may still undermine its effective-
ness. For example, BA requires participants to consider
the relationship between activity engagement and mood.
Participants are asked to identify and schedule meaning-
ful activities, remember to complete these activities and
then reflect on successes, failures and barriers. In BA, it
is hoped individuals acquire the skills and motivation to
maintain activity engagement after the course of BA
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sessions have concluded. There is a risk, therefore, that
despite the many features included to facilitate engage-
ment, individuals with marked memory and/or organisa-
tional difficulties arising from ABI may struggle to
complete the exercises and experience feelings of failure
and inadequacy. For this reason here we will compare a
traditional BA group (activity planning group) with a
more “hands on” experiential approach (activity engage-
ment group). In the latter group, participants will be en-
gaging in positive activities within the group (crafts,
games, art, discussions) without placing any demands on
planning, engaging and reporting back on activities from
everyday life. For these reasons, the activity engagement
group may be better accepted than the activity planning
group. Alternatively, the activity planning group may be
better accepted if it is perceived as “proper therapy” di-
rected at long-term change, rather than the temporary
engagement offered in the activity engagement group.
However, the activity engagement group is similar to
many social or activity-based groups already offered by
local charities including to people with ABI. As has been
pointed out [36], such groups are rarely if ever evaluated
relative to clinical services. Exploring differences in feasi-
bility and research outcomes between the two types of
groups are therefore key aims of this trial.
BA has shown strong effects both individually (d =
0.78) and in group (d = 0.74) settings in the non-ABI
population [25, 37, 38] as well as preliminary support (d
= 0.27 to 0.71) in one-to-one therapy in stroke [34], but
this is the first group BA evaluation, of which we are
aware, in ABI. There are clear economic advantages to
groups compared with individual therapy [39]. Beyond
this, treatment waitlists are reduced by utilising group
formats, hence potentially reducing long-term costs such
as days of missed work [40–42]. In addition, when they
work well, the supportive dynamics of groups of people
with similar challenges can enhance therapeutic effects
[36, 40].
Therefore, the proposed trial will investigate the feasi-
bility of two activity-based interventions and whether ex-
plicitly training individuals with an ABI to plan and
engage in meaningful activities is superior in terms of
acceptability and practicality, and explore whether either
intervention affects activity level and mood compared
with an equivalent period of waitlist controls.
Objectives
The primary objective of the Mood, Activity Participa-
tion, and Leisure Engagement Satisfaction (MAPLES)
trial is to determine the feasibility and acceptability of
two activity-based group interventions in individuals
with an acquired brain injury (ABI) with low mood. This
will be based on participant retention from baseline to
1-month post-intervention, acceptability of the proposed
skills in the group sessions and assessments, and partici-
pant feedback from the exit interview.
The secondary objective of the MAPLES trial is to ex-
plore whether either traditional or experiential behav-
ioural activation potentially leads to changes in mean
activity level and related outcomes including depression,
anxiety, post-traumatic stress, motivation, participation
and sense of control, compared to a waitlist control con-
dition at the group level in individuals with an ABI.
Trial design
The MAPLES trial is a parallel-arm randomised con-
trolled trial with nested qualitative research. Participants
will be allocated on a 1:1:1 ratio.
Methods
Participants, interventions and Outcomes
Study setting
Approximately 60 individuals with an ABI will be re-
cruited within the Cambridgeshire region of East of Eng-
land, UK; specifically those who are clients of
Cambridgeshire Community Services (CCS) NHS Trust.
The trial will take place in community-based clinics
within CCS. The list of trial sites can be obtained as part
of the trial registration documentation (NCT03874650)
on clinicaltrials.gov.
Eligibility criteria
Participants will be included in the trial if they meet the
following:
1. Have a diagnosis of an ABI1
2. Are a client of Cambridgeshire Community Services
3. Are 18 years of age or older
4. Speak and comprehend English
5. Are a minimum of 3 months post-ABI
6. Are identified as having low mood/reduced activity
level. These will be identified by the following:
(a) A score of at least 7 on the depression subscale
of the Hospital Anxiety and Depression Scale
(HADS-D [43])
(b) Clinician report (i.e. through the clinician’s own
administration of the HADS-D within the past
3 months of screening date or clinical interview
that has indicated a client has low mood/would
benefit emotionally from increased activity
level).
Participants will be excluded from the trial if they:
1This includes traumatic brain injury, stroke, anoxia/hypoxia,
encephalitis and other brain infections, and chemotherapy-related
neurotoxicity and resected brain tumours.
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1. Are incapable of attending to and/or understanding
the intervention materials, based on clinical
judgement from referrer (i.e. has receptive aphasia,
does not have capacity to consent and are unable to
live independently)
2. Have a diagnosis of dementia or other
neurodegenerative disorder
3. Are currently undergoing or due to undergo a
psychological intervention for low mood or
depression (e.g. CBT) during the timeframe of the
trial
4. Unstable psychotropic medication (i.e. has started
or changed medications within the past 6 weeks)
5. Are actively suicidal (i.e. have attempted suicide in
the past 3 months, currently self-harm and/or have
suicidal intentions in the near future), as identified
by the referring clinician
Interventions
The MAPLES trial consists of two interventions, each
designed to facilitate engagement in pleasant and mean-
ingful activities through two different approaches—the
activity planning group and the activity engagement
group. These groups will each meet once weekly for 1 to
1.5 h over 8 weeks. Group sizes will be at minimum 3 in-
dividuals and maximum 6 individuals. In order to ensure
that any benefits from each group are beyond treatment
as usual, the MAPLES trial will also run a waitlist con-
trol group, whereby participants will receive standard
care for 8 weeks and then be re-randomised to either the
activity planning or activity engagement group (see the
“Allocation—sequence generation” section for details on
allocation).
Therapist training and characteristics
Both the activity planning group and the activity engage-
ment group will be facilitated by AK. AK has an under-
graduate degree in psychology and a Master’s degree in
rehabilitation science that involved conducting research
with individuals with an ABI and has 8 years’ experience
volunteering with individuals with an ABI. AK has re-
ceived training on the intervention (approximately 6 h)
and regular supervisions from a registered clinical psych-
ologist (TM) and from senior members of the research
team (FCM and PVP).
Activity planning group
The activity planning group will take a “traditional” BA
approach to increasing engagement in meaningful and
positive activities. Generally, those receiving BA training
develop and maintain a schedule based on activities that
have been enjoyable, pleasant, meaningful, or interesting
in the past [25]. Clients are instructed to monitor their
daily mood and participation in these activities to
identify the connection between them and taught how
to increase the frequency and quality of positive events
[44, 45]. Along with the above, participants assigned to
the activity planning group will also learn about identify-
ing and challenging counter-productive patterns of
avoidance and procrastination as well as consider bar-
riers that may be a particular problem for people with
ABI, such as distraction and goal neglect, alongside
strategies that may help to overcome these [46, 47]. The
activity planning group will consist of weekly 1- to 1.5-h
group sessions over 8 weeks, covering 8 overarching
themes:
1) Introduction to group therapy
Participants are given an overview of behavioural
activation and the relationship of activity level to
mood. Participants are also provided information on
why planning activities is difficult after brain injury
and are introduced to mood monitoring and
monitoring lapses in attention.
2) Identifying enjoyable activities
Participants discuss their monitoring results and
learn about the relationship of mood to attention.
Participants begin identifying what goals they have
for themselves, activities that align with their goals
and values and schedule in the first activity using a
step-by-step approach.
3) Changing habits and planning pleasurable activities
Participants problem solve their activity from the
past week and identify barriers and facilitators
related to activity completion and discuss how the
activities made them feel. Participants then learn
about how activities become habitual and what
personal triggers prevent completion of an activity.
Participants plan in another activity.
4) Goal review and balancing enjoyable and routine
activities
Participants review their activity from the past week
and learn how to prevent barriers to activity
completion. Participants then review their goals
from week 2 and their daily schedules to reflect on
whether there are activities that are making them
feel down that could be altered or removed.
Participants plan in another activity.
5) Identifying solutions to goal attainment
Participants review their activity from the past
week. Participants learn to identify avoidance
patterns and how to create solutions to personal
triggers and avoidance patterns. Participants learn
how to prevent distraction from a task and plan in
another activity.
6) Increasing mastery and managing fatigue
Participants review their activity from the past
week. Participants discuss the potential benefits of
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consistently challenging themselves to increase
activity level and the risks of not increasing
mastery. Participants learn to recognise warning
signs of fatigue when attempting to increase activity
level. Participants plan in another activity and are
encouraged to increase overall activity level.
7) Active approaches to engagement
Participants review their activity from the past
week. Participants discuss the importance of social
relationships in maintaining a good mood and
barriers to taking initiative to plan activities with
other people. Participants practice directly initiating
activities with others and are encouraged to plan in
an activity with other people.
8) Relapse prevention
Participants review their activity from the past
week. Participants then review the content from the
past 7 weeks and list individual “take home”
messages from the group. Participants identify
personal triggers for relapse and create strategies to
overcome triggers should they encounter them.
Participants are encouraged to keep up activity
scheduling and planning in a stepwise fashion.
The above modules were designed in line with typical
BA interventions (for a review, see Kanter et al. [24]) as
well as accepted and effective rehabilitation strategies for
executive function impairment [47, 48]. Individuals with
an ABI and their family members were also interviewed
to determine what barriers and facilitators are present
when engaging in day-to-day and meaningful activities.
Activity engagement group
The activity engagement group will take a “hands on”
experiential approach to increasing activity level. Indi-
viduals randomised to this arm will meet weekly for 1 to
1.5 h for 8 weeks and engage in various potentially re-
warding or meaningful social activities such as board
games and crafts. Participants in this group will not re-
ceive specific training on increasing activity level outside
of these weekly sessions or overcoming barriers to par-
ticipation. Instead, the aim is that participants experi-
ence positive reinforcement within the activity
engagement group without explicitly scheduling activ-
ities outside of the group.
At the beginning of the 8 weeks, participants are told
of the MAPLES trial purpose and that one approach to
increasing activity level is to “learn by doing” and that as
part of the group they will take part in potentially inter-
esting/creative activities. Participants are offered sugges-
tions by the group facilitator (AK), such as board games,
t-shirt making, puzzles, painting, “pub quizzes”, figurine
painting, origami/papercraft, and clay sculpting. The ac-
tivities in this group were selected based on typical
activities organised by local ABI charities to promote en-
gagement in meaningful activities. Participants are also
told they are welcome to suggest activities to complete
within the group (e.g. social discussion only, customising
photo frames). There are no restrictions for activities to
only be conducted within one session—for example, par-
ticipants are free to choose to play board games
throughout the 8 weeks. We view this as analogous to
traditional BA whereby participants choose what activ-
ities they wish to plan outside of the group.
The activities within the group are meant to be activ-
ities that are feasible to recreate and complete within a
health care facility or community-based charity group
and thus should not have excessive financial costs or
limitations due to the structure of the facilities and
would not risk exclusion of participants who might be
physically incapable of completing the activities. For ex-
ample, completing paintings would be possible within a
group setting, but organising cooking sessions, trips out-
side the health care facility and expensive activities that
would require a large initial investment and sufficient
dexterity (e.g. carpentry) would not be suitable. Given
the focus of activity completion within the group, this
may implicitly or explicitly challenge negative beliefs
about engaging in meaningful activities and thus partici-
pants may maintain increased activity level and en-
hanced mood past the end of the group.
Waitlist control group
With respect to our secondary aims, in order to separate
any benefits gained from the activity planning or activity
engagement groups from benefits that might occur
spontaneously over an 8-week period, approximately a
third of participants will be first assigned to the waitlist
group. Given that individuals with an ABI might have
varying aspects/types of clinical care, the decision was
made not to ask participants to discontinue contact with
their normal clinical services. Hence, the waitlist group
forms a “treatment as usual” control arm. The waitlist
group will run for 8 weeks, after which participants will
complete a second baseline assessment and will then im-
mediately be re-randomised into either the activity plan-
ning or activity engagement group.
Intervention criteria
The above named interventions will be discontinued in
the event that participation in the groups results in harm
or deterioration of participants (e.g. worsening depres-
sion). We will monitor participants in two ways. Firstly,
where there are instances of reported thoughts about or
incidents of self-harm in the group, these will be re-
corded and managed through clinical supervision (e.g. to
inform whether relevant clinical services are informed).
Secondly, changes in mood questionnaire scores will be
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examined between baseline, time 2 and time 3 to estab-
lish whether the above criteria for discontinuing the
study have been reached. Where discontinuing criteria
have not been reached but individual participants show
deterioration leading to concern, this will be managed
on a case-by-case basis through clinical supervision, dis-
cussion and decisions about whether continuing to par-
ticipate is in that individual’s best interests and whether
clinical services need to become engaged. Adherence to
the treatment manual and trial protocol is managed by
the steering committee and is determined by audio re-
cordings of group sessions. Although the core elements
as listed above for each group will not change outside of
risk of harm to the participant, minor changes may be
introduced as the sessions progress. Examples could in-
clude changes to the text (homework sheets), images
(photos used to illustrate topic) and activities (games
within the activity engagement group) in response to in-
session acceptability of materials. Changes to worksheets
will be tracked. Participants will be allowed to seek treat-
ment throughout the course of the intervention for med-
ical difficulties (e.g. physiotherapy appointments), and
although we do not actively recruit individuals receiving
psychological services, if a participant already enrolled in
the trial decides to refer themselves to psychological ser-
vices, we would not discourage this. We will emphasise
that attendance within the MAPLES trial is still possible
if the participant has queries about attending both study
sessions and other clinical services. We would encourage
the participant to discuss trial participation with their
practitioner and remind the participant they are free to
withdraw from the study at any stage. Any new involve-
ment in psychological services will be documented and
reported as part of the trial data. This is viewed to be
the most ethical position whilst still maintaining suffi-
cient documentation of other services accessed within
the trial.
Treatment integrity and fidelity
Compliance with the trial protocol will be managed pri-
marily by regular review of recruitment strategies, inter-
vention delivery, and assessment administration. These
activities will be overseen by a Steering Committee
which has been assembled for this purpose and will meet
regularly over the course of the trial. The meetings will
include recruitment site initiation sessions to ensure that
all individuals involved in recruitment are identifying
participants in a consistent manner. Regular review of
documentation of evidence of eligibility will be con-
ducted by a member of the research team not involved
in the screening and recruitment process nor conducting
the intervention.
All group sessions will be audio recorded in order to
code the sessions for intervention fidelity. A member of
the research team not conducting the intervention will
listen to audio recordings of each session in order to de-
termine adherence to the protocol. Fidelity in the activity
planning group will be assessed by (1) identifying
whether the therapist covered the components outlined
in the fidelity checklists (see Additional files 1 and 2) in
a suitable manner (i.e. not skimmed) and (2) how con-
sistently techniques were applied across group cohorts.
Given the inherently flexible nature of the activity en-
gagement group, general principles rather than specific
content will be used to evaluate fidelity. For the activity
engagement group, the content covered in the activity
planning group should not be mentioned, and the core
components as listed in Table 1 should be present in
each session.
Assessment compliance at each time point (i.e. com-
pleting the full outcome measure battery at baseline,
post-intervention, and 1-month post-intervention) will
be completed using a checklist and comment section to
input any information as to why an assessment was not
fully completed. Any protocol deviations, whether acci-
dental or intentional, will be documented and reported
to the principal investigator (TM), and major concerns
to both TM and sponsor immediately.
Outcomes
The primary objective of this trial is to examine feasibil-
ity and acceptability of the activity planning group and
the activity engagement group to inform the design of
subsequent larger-scale studies. The secondary objective
of this trial is to explore the potential therapeutic benefit
of the activity planning group and the activity engage-
ment group relative to the waitlist group.
Primary objective—primary outcome measure There
is no single primary outcome measure to determine
feasibility and acceptability of the MAPLES trial. These
will be determined based on (1) ability to meet recruit-
ment targets, (2) attrition levels across the three groups,
(3) group attendance, (4) a post-study questionnaire
whereby participants are asked to rate aspects of their
group (i.e. perceived benefits of each session, suggestions
for improvements), and (5) qualitative data from the exit
interview from a subset of participants, which includes
questions about participants’ experience within each
group.
These outcomes will be evaluated based on specific
targets for each objective, as below:
1. For each cohort of groups, a minimum of 9 people
and maximum of 18 participants recruited
2. Attrition levels less than 20% across the three arms
of the trial
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3. Participants attending at least 5 of 8 sessions within
the activity planning and activity engagement group
4. Positive ratings of group aspects in the post-study
questionnaire
5. Minimal barriers to attendance and engagement in
groups, as evident in the qualitative data
Secondary objective—research outcome measure To
determine the secondary objective, the potential thera-
peutic benefit of the activity planning and activity en-
gagement groups, the Behavioural Activation for
Depression Scale (BADS [49]) will be used. Additional
descriptives of secondary outcome measures between
groups will also be conducted. Please see the “Methods:
data collection, management, and analysis” section for a
description of the BADS and the secondary outcome
measures.
Participant timeline
Participants will be recruited for approximately 18
months, and enrolled on a rolling basis. No run-ins or
washouts are planned as part of this trial. After the re-
search team has received a referral, participants will be
scheduled for a baseline assessment within 1 month
maximum of the current phase of groups. Following the
end the first phase of the activity planning group, activity
engagement group, and waitlist control group, time 2
and time 3 assessments will be held concurrently with
new time 1 baseline assessments for the subsequent
phases, which will lead to an approximately 1-month
gap in between phases of groups. Please see Fig. 1 for an
overview of the participant timeline. In effect, only one
group of both the activity planning and activity engage-
ment group will be running at any given time, with an
aim to enrol 6 cohorts of each group during the recruit-
ment timeframe.
Sample size
Although typically power calculations are conducted for
trials, the primary objective of the MAPLES trial is to
determine the feasibility and acceptability of the inter-
vention. Based on our previous experience [50, 51]
approximately 20 participants per arm (a total of 60 par-
ticipants) would provide a sufficient balance between de-
termining feasibility and exploring potential mediators
of outcome between the activity planning group and ac-
tivity engagement group that can guide the development
of a future larger-scale trial.
Recruitment
All participants will be recruited through ABI clinical
services within Cambridgeshire Community Services
(CCS) NHS Trust. The clinical staff within CCS will first
identify participants from their records of clients cur-
rently or previously associated with the service. Upon
identification of potentially suitable clients, the clinical
staff will either (1) provide an invitation letter in person
to a client that meets eligibility criteria or (2) post or
email invitation letters to any client meeting eligibility
criteria. The invitation letter will provide a brief over-
view of the trial and its procedures and a summary of
the two groups. If clients are interested they will be
given the option to give written consent for their clin-
ician to pass on client contact information to the re-
search team who would then approach the client (via
phone call, SMS, email, mail, or in person meeting).
Once contact is made, the research team will first con-
firm eligibility criteria, after which an appointment will
then be made to take written informed consent and con-




The MAPLES trial will use pre-determined blocked ran-
domisation. The trial statistician will conduct a
computer-generated, pseudo-random allocation prior to
beginning recruitment. Each participant will be assigned
a code, whereby A = activity planning group, B = activity
engagement group and WL = waitlist control group.
Participant blocks are of varying length, unknown to all
authors and researchers with the exception of the trial
statistician (PW). Varying block lengths were used in
order to reduce the likelihood of researchers guessing
Table 1 Core components of each group
Activity planning group Activity engagement group Waitlist control group
• Activity scheduling and monitoring • Participant autonomy • No contact with research team during wait
• Identifying avoidance patterns • Direct experience of selected
activity
• No in-depth information about either study group
• Problem-solving barriers to activation • Focus on social engagement • Not actively discouraged from continuing other forms of
care
• Step-by-step activity planning • Non-linear group structure
• Enhancing planning through goal
management
• No explicit planning of activities
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the group allocation of participants based on the alloca-
tion of previous participants.
Participants first assigned to the waitlist control
group will be re-randomised to either the activity
planning group or the activity engagement group
again using pre-determined blocked randomisation by
the trial statistician prior to commencement of the
trial.
Allocation concealment mechanism and implementation
Following sequence generation, the trial statistician
will simply write each code onto an individual card
and seal it into an opaque envelope marked only with
the participant number. Once generated, these enve-
lopes will then be passed onto the researcher con-
ducting the baseline assessments and participant
enrolment. After conducting the baseline assessment,
Fig. 1 Participant flow diagram with expected numbers. AP, activity planning; AE, activity engagement; WL, waitlist control
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the researcher will simply open the next envelope in
sequence. A second batch of 20 opaque sealed enve-
lopes that indicate whether the participant is to be
re-allocated to the activity planning group (A) or the
activity engagement group (B) will be created. This
randomisation is conducted independently of the first
randomisation procedure. Again, once a second base-
line has been performed by the researcher (required
prior to re-randomisation), the researcher will open
the second envelope in sequence to determine alloca-
tion for those first assigned to the waitlist control
group. As all randomisation envelopes are created
prior to enrolment, we assume a priori that those al-
located to the waitlist control group will experience
an improvement once re-randomised to either the ac-
tivity planning group or activity engagement group
and completing either group, hence assuming they re-
quire further treatment. In order to mitigate bias, all
researchers conducting outcome assessments will not
be involved in opening any of the envelopes for
participants.
Blinding
Clinicians recruiting participants will be unaware of
what group participants will be assigned to. In this sense,
randomisation is conducted blind to any information
about the participants and cannot influence or be influ-
enced by the outcome of the baseline assessments. Given
that it is a psychological intervention, it will be impos-
sible to blind either the researcher delivering the inter-
vention or the participant to what condition they have
been assigned to.
The researcher conducting the outcome assessments
(time 2 and time 3) will be blinded to the group that
each participant has attended. If unblinding occurs prior
to the time 2 and time 3 assessments (e.g. participant
forgets to not inform researcher, gives information that
makes it obvious what group they were in), then another
researcher will be assigned to conduct the time 2 and
time 3 assessments, provided a feasible timeframe and
availability of researchers. If unblinding occurs within
one of the time 2 and time 3 assessments (e.g. partici-
pant mentions group status whilst the researcher is help-
ing the participant complete the outcome measures),
then such an incident will be recorded and reported in
the final paper.
As the exit interview will ask specifically for feedback
on their experience within either the activity planning or
activity engagement group, it will be impossible to blind
the researcher or the participant as to what condition
they have been assigned to. Therefore, the exit interview
will be conducted only after the time 3 outcome mea-
sures have been completed.
Methods: data collection, management and analysis
Data collection methods
The outcome measures battery will be administered at
baseline (time 1), post-intervention (time 2) and 1-
month post-intervention (time 3) either in person, via
post, or using online questionnaire software as per the
convenience of the participant. Participants who are first
randomised to the waitlist control group will complete a
second baseline assessment prior to being re-
randomised into either the activity planning group or
the activity engagement group. All researchers conduct-
ing assessments will receive training relative to working
with individuals with an ABI, and a walk-through of the
assessment protocol.
Demographic information, including recruitment site,
age, gender, years of education, ethnicity and the pres-
ence of a caregiver at home, is also recorded. At the time
of written informed consent, participants will also be
asked for consent to access their CCS medical records
for details of the nature of their injury such as injury
type and location within the brain. Participants who re-
fuse to give access to their medical records will still be
welcome to participate in the trial. The data collected
from CCS medical records includes the following:
1. Date and type of ABI (e.g. TBI, stroke, hypoxia) and
mechanism/cause (e.g. road traffic accident, high
blood pressure, heart attack)
2. Any details on parts of the brain affected and how
indicated (e.g. frontotemporal damage, CT scan)
3. Any details on length of stay in acute care
4. Date of initial assessment within CCS and
rehabilitation services received
5. Severity of injury and how indicated (e.g. Glasgow
Coma Scale scores, Loss of Consciousness, Post-
traumatic Amnesia, Stroke Severity Scale)
6. Any health-related comorbidities (e.g. diabetes, al-
cohol dependence)
7. Any available data on the Dysexecutive
Questionnaire [52, 53] and the European Brain
Injury Questionnaire [54], both self and informant
8. Any available data on neuropsychological
assessment (e.g. Wechsler Adult Intelligence Scale)
9. Any information on previous diagnosis of
depression or other mental health disorder and
treatment of depression (e.g. counselling,
psychologist, therapist)
10. Any information on antidepressant medication
(dosage and duration)
Secondary objective—research outcome measures
The Behavioural Activation for Depression Scale (BADS
[49, 55];) is a 25-item measure of avoidance and activa-
tion behaviours considered to underlie depression.
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Participants are asked to give responses based on the
previous week. The BADS consist of 4 subscales: activa-
tion (“I was an active person and accomplished the goals
I set out to do”), avoidance/rumination (“I did things to
avoid feeling sadness or other painful emotions”), work/
school impairment (“My work/schoolwork/chores/re-
sponsibilities suffered because I was not as active as I
needed to be”) and social impairment (“I was not social,
even though I had opportunities to be”). Items are rated
on a 7-point Likert scale, ranging from 0 (not at all) to 6
(completely). Total scores can either be calculated per
subscale, or the scale total can be used. Higher scores in-
dicate greater behavioural activation. Total scores can
range from 0 to 150. The BADS has good factor struc-
ture, internal consistency and test-retest reliability as
well as good construct validity [49, 55].
Secondary outcome measures
The Hospital Anxiety and Depression Scale (HADS [43])
The HADS is 14-item self-report measure of symptoms
of anxiety and depression. Seven of its questions pertain
to anxiety, whilst the other seven pertain to depression.
Participants rate items on a 4-point Likert scale, from 0
(not at all) to 3 (most of the time). Examples of items
are “I have lost interest in my appearance” and “I feel
restless as if I have to be on the move.” Total scores for
the anxiety and depression subscales can range from 0
to 21 on each subscale, with greater scores indicating
greater anxiety or depression. Initially developed for pa-
tients with physical health problems, the HADS two-
factor structure has been supported in ABI samples [56,
57]. The HADS has excellent internal consistency and
strong convergent validity with other measures of de-
pression and anxiety in TBI samples [58, 59].
The Behavioural Inhibition Scale/Behavioural Activa-
tion Scale (BIS/BAS [60];) is a 20-item measure that as-
sesses behavioural approach or avoidance motivational
systems that underlie behaviour. The BAS portion con-
tains 3 subscales: drive (“I go out of my way to get things
I want”), fun seeking (“I crave excitement and new sen-
sations”) and reward responsiveness (“When I get some-
thing I want, I feel excited and energised”), whilst the
BIS portion is a single subscale (“I worry about making
mistakes”). Items are rated on 4-point Likert scale, ran-
ging from 1 (strongly agree) to 4 (strongly disagree).
Scores on the drive and fun seeking subscales range
from 4 to 16, reward responsiveness from 5 to 20, with
higher scores indicating greater activation. The BIS scale
ranges from 7 to 28, with higher scores indicating
greater inhibition. The BIS/BAS subscales have demon-
strated good internal consistency, and the three BAS
subscales load strongly on a second-order factor separate
from the BIS [60]. The BIS/BAS also has adequate test-
retest reliability and has demonstrated convergent and
discriminant validity [60].
The Intolerance of Uncertainty Scale—Short Form (IU-
SF [61];) is a 12-item measure of responses to uncer-
tainty, ambiguous situations and the future. The IU-SF
has two subscales: prospective IU (“I always want to
know what the future has in store for me”) and inhibi-
tory IU (“When it’s time to act, uncertainty paralyses
me”). Items are rated on a 5-point Likert scale ranging
from 1 (not at all characteristic of me) to 5 (entirely
characteristic of me). Scores on prospective IU range
from 7 to 35, and scores on inhibitory IU range from 5
to 25. Greater scores indicate greater difficulties with ei-
ther prospective of inhibitory IU. The IU-SF has a stable
two-factor structure and has demonstrated good internal
consistency, convergent and discriminant validity [61,
62]. This measure was included to investigate whether
changes in IU relates to changes in activity level (mea-
sured via the BADS) in ABI.
The Impact of Events Scale-Revised (IES-R [63]) is a
22-item measure that assesses post-traumatic symptoms
within the past week. The IES-R has three subscales: in-
trusion (“Any reminders brought back feelings about
[my injury]”), avoidance (“I tried not to talk about [my
injury]”) and hyperarousal (“I was jumpy and easily star-
tled”). Items are scored on a 5-point Likert scale ranging
from 0 (not at all) to 4 (often). Scores on intrusion and
hyperarousal range from 0 to 35, and scores on avoid-
ance range from 0 to 40. The total scale ranges from 0
to 110, with greater scores indicating greater post-
traumatic stress. Cronbach’s alpha of the subscales is
high in patients with burn injuries [64] and inpatients
with life-threatening cardiac events [65]. The IES-R has
acceptable discriminative validity when distinguishing
patients with and without PTSD after motor vehicle ac-
cidents (sensitivity = 0.74, specificity = 0.63) and has
demonstrated good convergent, divergent and concur-
rent validity [66].
The Brain Injury Rehabilitation Trust Motivation
Questionnaire-Self (BMQ-S [67]) is a 34-item question-
naire that measures levels of motivation in ABI popula-
tions. Questions are rated on a 4-point Likert scale,
which participants can answer always, often, sometimes
and never to questions. Total scores range from 34 to
136, with higher scores indicating greater difficulties
with motivation (i.e. not motivated). Examples items in-
clude “I plan my week and make arrangements for
things to do” and “Someone has to tell me what to do
each day.” The BMQ-S has an internal consistency of
0.94 and has a strong relationship with the Apathy
Evaluation Scale (r = 0.67). The BMQ-S has also been
found to have good test-retest reliability (ICC = 0.85
[68];) and a high Guttman split-half reliability coefficient
(0.90) [67].
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The Motivation for Traumatic Brain Injury Re-
habilitation Questionnaire (MOT-Q [69]) is a 31-item
scale designed to measure motivation for rehabilita-
tion activities in ABI. It consists of four subscales:
lack of denial (“I have always had the problems I am
having now” [reverse scored]), interest in rehabilita-
tion (“Rehabilitation is very useful”), lack of anger
(“Rehabilitation therapists can’t help me with my
problems” [reverse scored]) and reliance on profes-
sional help (“I rely on doctors to help me with my
problems”). It uses a 5-point Likert scale rated from
− 2 to + 2 (strongly disagree to strongly agree). Total
scores range from − 62 to + 62, with higher scores in-
dicating greater motivation for rehabilitation. Cher-
vinsky et al. [69] reported the MOT-Q total score
had a Cronbach’s alpha of 0.91, and a Cronbach’s
alpha of 0.86, 0.86, 0.83 and 0.73 for the subscales
lack of denial, interest in rehabilitation, lack of anger
and reliance on professional help, respectively. The
MOT-Q has additionally been found to have good
test-retest reliability [68].
The Modified Outcome Measure—Participation Ob-
jective, Participation Subjective (MOM-POPS [70];) is a
shortened version of the original POPS scale. The POPS
was originally designed to be a measure of community
integration in individuals post-TBI, with the scale aimed
at producing a Participation Objective score and a Par-
ticipation Subjective score. In the MOM-POPS, partici-
pants are asked to rate their participation in household,
occupational and social activities in the past week, based
on (1) an estimate of the amount of household, occupa-
tional, and social activities engaged in within the past
week (Participation Objective score);( 2) whether they
would like to be doing more, less or the same of these
activities (Participation Subjective score); and (3)
whether these activities are the most, very, moderate, a
little or not at all important to their satisfaction with life.
Participants are then asked to circle from a list of op-
tions (e.g. cleaned the house, volunteer work, made so-
cial arrangements) which activities they have engaged in
within the past week and have the option to list any add-
itional activities they have engaged in. Although the dif-
ficulty of assessing the reliability and validity of a
measure that provides both objective and subjective data
has been discussed [70], the original POPS has shown
acceptable internal consistency and good test-retest reli-
ability and has good ecological validity.
The Snaith-Hamilton Pleasure Scale (SHAPS [71];) is
a 14-item measure of hedonic capacity within the past
few days. Items are rated either strongly disagree, dis-
agree, agree or strongly agree. If a participant responds
to either disagree category they receive a score of 1, and
if they respond to either of the agree categories they re-
ceive a score of 0. Hence, the scale total range is 0 to 14,
with higher scores representing greater anhedonia. Ex-
ample items include “I would enjoy a warm bath or a re-
freshing shower” and “I would be able to enjoy a
beautiful landscape or view.” The SHAPS has shown
high internal consistency, convergent and discriminant
validity and test-retest reliability in clinical and non-
clinical populations [71–73].
The Sense of Control Scale (SCS [74, 75];) is a 12-item
measure of an individual’s perceived ability to exert con-
trol over their life. It consists of two subscales: personal
mastery (“I can do just about anything I really set my
mind to”) and perceived constraints (“There are many
things that interfere with what I want to do”). Items are
rated on a 7-point Likert scale, ranging from strongly
disagree to strongly agree. Total scores can range from
12 to 84. Factor analysis has supported its two-factor
structure, with each subscale having adequate internal
consistency (0.70 and 0.86, respectively [74]).
The Credibility/Expectancy Questionnaire (CEQ) is a
6-item measure of participant expectations of treatment
outcome and perceived credibility of the treatment [76].
It consists of two factors, expectancy (“How much im-
provement in your symptoms do you really feel will
occur?”) and credibility (“How logical does the therapy
offered to you seem?”). The two-factor structure of the
CEQ is supported, and has high internal consistency and
test-retest reliability [76]. This measure will only be
given at time 1.
The Post-Study Questionnaire (PSQ) was designed to
obtain general feedback from the MAPLES trial. Partici-
pants will provide “top of mind” responses to questions
focused around enjoyment of the group and factors in-
volved in group attendance, such as “Do you see any
benefits to being part of group sessions?” and “Do you
feel there are any barriers to you participating in group
sessions?” Participants are encouraged to provide any
additional comments to support their answers, or com-
ment on any topic that was not specifically addressed in
the PSQ.
The exit interview
Approximately 20 participants will be randomly selected
to take part in an exit interview at time 3. If a participant
is selected to complete the exit interview, they will be
asked a series of in-depth question to gain more specific
feedback about the groups and their experiences within
it. Examples and prompts are used to facilitate recall of
the groups. The interview begins with general responses
to group therapy, including items such as “Can you give
your general thoughts on participating in the group?”
and “Do you think [the therapist] had any impact on
how you responded to the group?” If participants took
part in the activity planning group, they were asked to
comment specifically on the content and materials of
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the group, with questions around the value of mood
monitoring, scheduling in activities, and barriers to
homework completion. Finally, all participants are asked
about practical aspects that may have affected their par-
ticipation, such as a relationship with a partner or close
friend, transport or health difficulties or their relation-
ship with other group members.
Along with the above measures, participants in the ac-
tivity planning group will be asked to submit a copy of
their activity schedules that they will be completing as
part of the group in order to provide a summary of types
of activities engaged in as part of BA trial.
In order to promote participant retention, individuals
who agree to take part will receive travel reimbursement
for each session attended (time 1, 2, 3, and group ses-
sions) as well as £50 compensation at the time 3 assess-
ment. Scheduling of assessments and group sessions will
be flexible based on the preference of trial participants’
availability; hence, the days in which group sessions
occur will likely differ across phases of the trial. If a par-
ticipant discontinues participation in the group sessions,
the research team will approach them and ask if they are
still interested in completing the outcome assessments
(time 2 and time 3).
Data management
All participants will have a unique anonymised trial ID
for the purposes of data collection and management.
Data entry will be completed by an independent re-
searcher with no knowledge of group allocation and will
only be given the questionnaires labelled with the trial
specific ID and be kept separately from any other trial
documentation with a password not known to the re-
searcher conducting the interventions. If any of the out-
come measures have missing items, the total score will
be estimated by using averaged responses from answered
items. Any participant with more than 20% of items
missing from any of the above measures (e.g. more than
2 items missing on a 10-item scale) at any time-point
will be treated as a missing value.
Upon completion of data collection and entry, the
dataset will be given to AK to match to the master list of
participants in order to conduct analyses. Individuals
that were first randomised to the waitlist control group
and completed a new baseline will have their data
restructured before analysis. Firstly, the time 2 assess-
ment for waitlist control participants will still be used as
is, but will also be used as a new time 1 assessment as
part of the subsequent group (whether activity planning
or activity engagement). Prior to analysis, all data will be
double checked by AK against the raw questionnaire
scores through double entry. Initial visualisation of the
data and summary statistics will be used to detect ex-
treme or impossible scores. Physical data (e.g.
questionnaires) will be stored in a secure locked filing
cabinet, separate to any personally identifiable informa-
tion. All data will be stored on a secure drive within the
department, accessible only to the research group,
Statistical methods
Quantitative and qualitative data analysis will be con-
ducted by AK and supervised by senior members of the
research team (TM, FCM, PVP) and the trial statistician
(PW). No interim analyses are planned.
To determine the feasibility of the trial, percent esti-
mates of recruitment rates will be calculated (number of
participants consented vs numbers of eligible partici-
pants vs total potential participants). A CONSORT flow
diagram will be used to visualise the number of partici-
pants screened, assessed for eligibility, found eligible,
consented to participate, and subsequent allocation and
assessment attendance. Percent attrition rates, what
point attrition occurred and number of sessions
attended per participant along with ratings of satisfac-
tion within each group will be calculated to inform con-
clusions about the acceptability of the trial. Missing data
points from the assessment period will also be reported.
Protocol deviations and reasons for drop out and non-
attendance (if available) will be reported.
Quantitative data will be analysed using R statistical
software package [77]. Demographic variables of the par-
ticipants allocated to each group will be reported. Means
and standard deviations, both with 95% confidence inter-
vals, of measures will be reported for all three groups at
each time-point. Data will be analysed using an
intention-to-treat analysis by including all randomised
participants into our analysis. In order to determine if
the treatment effect is constant at initial randomisation
and at re-randomisation, average change scores will be
reported for those first randomised to the waitlist con-
trol group and for those randomised directly to either
the activity planning or activity engagement group.
An exploratory analysis will then be conducted to as-
sess the effectiveness of the activity planning and activity
engagement groups. A generalised linear mixed-effects
model with maximum likelihood estimation and an un-
structured covariance matrix using the primary outcome
measure, the BADS, across the multiple assessment
points will be used. As only those in the waitlist control
group will be re-randomised, there are unlikely to be
carry-over effects that influence treatment effects in the
subsequent group allocation. Thus, treatment effects of
these individuals are not expected to differ from partici-
pants allocated to the activity engagement and activity
planning groups in the initial randomisation period. A
residual covariance matrix will be used to investigate
homogeneity of variance. Participant intercept and slope
will be used as the random effects, with group status
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(activity planning vs activity engagement vs waitlist con-
trol) as the fixed effect. If the data is found to not have a
linear structure and/or the random intercept, random
slope model fails to converge, a random intercept model
will instead be conducted. Although mixed-effects
models provide appropriate type I error corrections, if
the final sample size is smaller than anticipated, type 1
error rates will be corrected prior to conducting the ana-
lysis. Generalised eta squared will also be reported based
on this analysis.
The minimal clinical important difference (MCID) of
the BADS will additionally be estimated to inform a
power analysis for a future definitive trial. The MCID
will be used in conjunction with feasibility (i.e. recruit-
ment rates) and acceptability (i.e. exit interviews) data in
a decision on whether to progress to a main trial. Given
the statistical limitations associated with using the
MCID to inform a power analysis with small sample
sizes [78], the MCID will not be estimated if 40 partici-
pants or less are recruited. All statistical results will be
reported as purely exploratory and care will be taken to
report all results as such.
The potential effect of demographic variables will also
be explored. Change scores on the BADS will be sum-
marised across gender, educational status, type of brain
injury, injury severity and location of lesion/injury. The
potential effect of time since injury on outcome mea-
sures will be summarised informally by whether individ-
uals are within the first year, second year, third year or
greater than 3 years-post injury. When exploring poten-
tial effects of the groups, change scores will be sum-
marised between those with and without antidepressant
medication in order to detect any potential influence of
medication on scores. All subgroup results will be de-
scriptive only, will be emphasised within the final paper
as exploratory and will only be provided as a supplemen-
tary document.
Qualitative data from the exit interview will be used to
inform the acceptability and practicality of the activity
planning and activity engagement group. Data will be
analysed using an interpretive description framework, a
technique developed to identify clinically relevant infor-
mation in complex health care populations [79]. The
qualitative data will be organised into relevant themes
that either facilitated or prevented a participant from
benefitting from the trial.
Qualitative data will be approached with a constructiv-
ist epistemological stance. Interviews will be analysed
using a constant comparative analysis and will follow the
steps outlined by Braun and Clarke [80] in creating and
coding themes. Any field notes or transcription notes
will be used to supplement the analysis. In order to in-
crease transferability, thick description of the participant
demographics, interviewer experience and training and
services provided at the recruitment sites will be re-
ported. Given that approximately 30% of the sample (20
participants) will provide interviews, saturation will be
determined when no new information meaningfully af-
fects the thematic map. The building of themes will be
triangulated using data from the quantitative outcome
measures and interpretation will be formed using behav-
ioural activation theory as an analysis framework. The
interpretation of themes will be in part discussed with
the Steering Committee service user in order to enhance
the credibility and hence the trustworthiness of the re-
sults. Confirmability and dependability of the data will
be supported through informal member checking with
participants during the interview, and peer debriefing




A data management committee was found to be un-
necessary, given the small scale of the trial, and as such
will be managed by the Steering Committee. Given that
the MAPLES trial is a pilot feasibility trial predomin-
antly, a formal Data Monitoring Committee was deemed
unnecessary given the modest number of participants
expected to be recruited relative to the amount of data
points. No interim analyses will be conducted. The trial
lead, principal investigator and trial statistician (AK,
TM, PW) will have full access to the final dataset. Re-
sults of the current trial will be reported as per CON-
SORT recommendations.
Harms
The management and reporting of adverse events will be
conducted as per the recommendation of the UK Med-
ical Research Council protocol. Although participants
may experience distress discussing their difficulties with
engaging in meaningful activities, this is considered a
normal aspect of psychological therapies. Necessary pre-
cautions have been taken to reduce the chance of an ad-
verse event occurring (i.e. excluding participants with
suicidal intent). In the unlikely case of an adverse event,
details will be reported in the final trial paper. Any con-
cerns about the well-being of a participant will be dis-
cussed in both clinical supervisions and in Steering
Committee meetings about the best way to ensure the
best outcome for the participant.
Auditing
Auditing will be conducted as part of the Steering Com-
mittee meetings. Regular site visits (at least once every 2
months) will be completed in order to review referral
and enrolment rates and consistent application of re-
cruitment strategies. Auditing of safety procedures,
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including risk of harm, participant consent and safe-
guarding concerns of the trial will be investigated as part
of the regular clinical supervisions of the intervention
therapist (AK) and a clinical psychologist (TM), held
weekly when groups are currently running.
Ethics and dissemination
Research ethics approval
This trial has received ethical approval from the Health
Research Authority of the UK National Health Service
(East of England—Cambridge Central, REC reference
18/EE/0305). The trial was registered at ClinicalTrials.-
gov on 12 March 2019 (NCT03874650) where the proto-
col can be accessed.
Protocol amendments
Any amendments will be immediately reported to the
trial sponsor, the recruitment sites and appropriately
submitted to the Research Ethics Committee after ap-
proval from all Steering Committee Members has
been given. Modifications to the protocol will add-
itionally be reported on the protocol registration
(NCT03874650).
Consent
All participants recruited will be taken through an in-
formed consent process prior to beginning participation
in this trial and have the opportunity to withdraw con-
sent at any time. Consent to participate will be obtained
by a member of the research team.
Confidentiality and access to data
The risk of a breach of confidentiality is managed by
the research being conducted in accordance with best
practice. Personally identifiable information (“PID”—
names, addresses, dates of birth etc.) are kept strictly
separate from fully anonymised research data (ques-
tionnaires, session recordings). PID are held in a se-
cure “haven” on departmental university computer
server and/or locked filing cabinets and will be
retained for only 12 months after the last participant
has completed the trial (in case of a need to re-
contact), after which they will be deleted.
At the time of consent, we make potential participants
aware that there are limits to our duty of confidentiality
if information is disclosed that indicates a significant risk
of harm to the participant or another individual. If such
a disclosure occurs, we will follow our standard operat-
ing procedures of alerting the individual’s GP (in the
case of self-harm) or appropriate protection agencies (in
the case of harm to others). Paperwork and files relating
to trial participants will be stored in locked filing cabi-
nets at the university department, only accessible by the
research team. Personally identifiable data and
anonymised data will be stored separately in order to de-
crease the risk of breaches to confidentiality. Only the
research team will have access to personal information
(contact details) for the purposes of contacting partici-
pants. The research team will only access medical re-
cords once for the purposes of collecting injury-related
information. Medical information will not be stored with
participant contact information and will only be linked
to anonymised participant indicators. The research data
(questionnaires, administered in person, by post or on-
line) will only contain anonymised participant indicators.
Ancillary and post-trial care
In the unlikely event that a participant suffers harm
from the trial, the trial sponsor will provide appropriate
compensation. Local university and MRC policy will be
followed to document and report the adverse event.
Dissemination policy
All participants will be given the option to receive a
summary of the trial results and have the opportunity to
discuss them with the research team. Trial results will
be shared in traditional methods such as journal publica-
tions, presentation at conferences and through social
media. Results will also be disseminated to the recruit-
ment sites, as well as to other research groups within the
university. The final quantitative dataset along with the
statistical code will be published and freely available to
third parties for review. Qualitative transcripts will be
made available only once transcripts have been suffi-
ciently modified to remove any contextual information
that might identify a participant (e.g. mention’s partner’s
name, hometown, etc.).
Limitations
Although many steps have been taken to reduce risk of
bias, envelopes as a method of allocation concealment
has been associated with bias in trials and thus should
be considered when interpreting results.
Discussion
Depression and low mood affect at least one third of
individuals with an ABI (which may be a rather con-
servative estimate), and many of those with depres-
sion receive treatment [81, 82]. One of the major
barriers to successfully treating depression and other
mental health disorders in ABI is the need for an
intervention that addresses the complex needs of the
population [20]. Various studies have documented the
link between lowered activity level and depression in
ABI [28, 35, 83–85]; hence, investigating whether BA
is a feasible, acceptable and potentially efficacious
treatment is warranted—particularly with group deliv-
ery, as is done here. The simplicity, whether
Kusec et al. Pilot and Feasibility Studies           (2020) 6:135 Page 14 of 17
combined with strategies to enhance planning and en-
gagement in meaningful activities or not, and the fact
that it does not need to be delivered by a clinical
psychologist [86], make it a potentially attractive op-
tion for service provision that has the potential to im-
mediately influence and benefit ABI services.
Understanding differences in feasibility and research
outcomes between the activity planning and activity en-
gagement groups is also essential to the development of
affordable and effective treatments. The activity engage-
ment group does not explicitly highlight the relationship
between low mood and activity level; hence, it may pro-
duce short-term mood gains that do not generalise to
changes in everyday life—the ultimate aim of BA. How-
ever, in the context of low levels of activity that fre-
quently accompany ABI, it is possible that simply
experiencing positive reinforcement through social en-
gagement will lead to explicit or implicit learning of the
relationship between mood and activity level that could
foster increased activity engagement beyond the group.
It is notable that implicit forms of learning are often
relatively well preserved even when explicit memory is
highly compromised [87]. The cognitive demands of the
activity planning group, even when modified for ABI,
may negatively affect acceptability relative to the activity
engagement group. If the activity engagement group is
well accepted, recreating and running such a group
could be easily recreated without extensive preparation
and cost.
Providing initial data on why a group intervention
is well accepted is also important. Within a standard
single group vs treatment-as-usual or waitlist control
design, the question would arise of whether it was
the BA component or simply the social experiences
of being in a group that was responsible for any
gains. The current trial design, by contrast, would
allow exploration of factors associated with group at-
tendance, attrition and potential variables of change
between groups. Similarly, if the groups are both
comparably well accepted, we might conclude that
the activity scheduling elements etc. of BA may add
little beyond the social group activity context in terms
of feasibility. Were the activity engagement group to
prove most effective, we would have stronger grounds
to conclude that the cognitive elements (i.e. planning
and organisational skills) used in BA and the more
business-focused nature of the sessions may have
undermined its acceptability in ABI.
Trial status
The first participant consented to the MAPLES trial on
May 20, 2019. Recruitment is planned to continue until
April 2021.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s40814-020-00660-8.
Additional file 1. MAPLES Pilot Feasibility Trial Fidelity Assessment
Checklist. Activity Planning Group.
Additional file 2. MAPLES Pilot Feasibility Trial Fidelity Assessment
Checklist. Activity Engagement Group.
Acknowledgements
The authors would like to thank a service user and the clinical staff of
Cambridgeshire Community Services for their tremendous support they have
provided in setting up this trial.
Authors’ contributions
AK was responsible for the trial conception and design, creation of trial
materials, obtaining ethics approval, collaborating with CCS NHS Trust to
initiate the research trial, wrote the first version of the manuscript and
coalesced feedback from the co-authors into the final version. TM, FCM and
PVP provided significant supervision and guidance toward the final trial de-
sign and protocol for ethical approval. EC, CL, CM and AB provided clinical
input into the relevance of the design to CCS ABI populations and the feasi-
bility of the initial design and are significant contributors to trial recruitment.
PW gave consultation for the statistical methods and randomisation proced-
ure and conducted blinded randomisation of participants. All authors read
and approved the final manuscript.
Funding
This trial is supported by funds awarded by the Medical Research Council to
TM (SUAG/049). AK is supported by the Gates Cambridge Trust Scholarship.
Availability of data and materials
Not applicable to the protocol. The dataset generated will be made available
to the public upon completion of the trial on the trial’s protocol registration
record (NCT03874650).
Ethics approval and consent to participate
This trial has received ethical approval from the Health Research Authority of
the UK National Health Service (East of England—Cambridge Central, REC
reference 18/EE/0305). The trial will adhere to MRC professional ethical




The authors declare that they have no competing interests.
Author details
1MRC Cognition and Brain Sciences Unit, University of Cambridge, 15
Chaucer Road, Cambridge CB2 7EF, UK. 2Evelyn Community Head Injury
Services, Cambridgeshire Community Services, Dynamic Health Building,
Brookfields Hospital, 351 Mill Road, Cambridge CB1 3DF, UK. 3The National
Hospital for Neurology and Neurosurgery, University College London
Hospitals NHS Trust, Post Box 113, Queen Square, London WC1N 3BG, UK.
4School of Health and Social Care, University of Essex, Wivenhoe Park,
Colchester CO4 3SQ, UK.
Received: 6 February 2020 Accepted: 3 August 2020
References
1. Cattelani R, Zettin M, Zoccolotti P. Rehabilitation treatments for adults with
behavioural and psychosocial disorders following acquired brain injury: A
systematic review. Neuropsychol Rev. 2010;20:52–85. https://doi.org/10.
1007/s11065-009-9125-y.
2. Headway UK. Acquired brain injury: the numbers behind the hidden
disability. Available from: https://www.headway.org.uk/media/7865/
acquired-brain-injury-the-numbers-behind-the-hidden-disability-2018.pdf.
Accessed 13th Apr 2020.
Kusec et al. Pilot and Feasibility Studies           (2020) 6:135 Page 15 of 17
3. Stroke Association UK. State of the nation: stroke statistics. Available from:
https://www.stroke.org.uk/sites/default/files/state_of_the_nation_2017_
final_1.pdf. Accessed 13th Apr 2020.
4. Howell K, Grill E, Klein AM, et al. Rehabilitation outcome of anoxic-ischaemic
encephalopathy survivors with prolonged disorders of consciousness.
Resuscitation. 2013;84:1409–15. https://doi.org/10.1016/j.resuscitation.2013.05.015.
5. McKinney PA. Brain tumours: incidence, survival, and aetiology. J Neurol
Neurosurg Psychiatry. 2004;75(suppl 2):ii12–7. https://doi.org/10.1136/jnnp.
2004.040741.
6. Granerod J, Cousens S, Davies NW, et al. New estimates of incidence of
encephalitis in England. Emerg Infect Dis. 2013;19:1455. https://doi.org/10.
3201/eid1909.130064.
7. Parsonage M. Traumatic brain injury and offending: an economic analysis.
London: Centre for Mental Health; 2016.
8. Saka Ö, McGuire A, Wolfe C. Cost of stroke in the United Kingdom. Age
Ageing. 2009;38:27–32 https://doi.org/10.1093/ageing/afn281.
9. Roozenbeek B, Maas AIR, Menon DK. Changing patterns in the
epidemiology of traumatic brain injury. Nat Rev Neurol. 2013;9:231–6
https://doi.org/10.1038/nrneurol.2013.22.
10. Teasell R, Bayona N, Marshall S, et al. A systematic review of the
rehabilitation of moderate to severe acquired brain injuries. Brain Inj. 2007;
21:107–12 https://doi.org/10.1080/02699050701201524.
11. Turner-Stokes L. Evidence for the effectiveness of multi-disciplinary
rehabilitation following acquired brain injury: A synthesis of two systematic
approaches. J Rehabil Med. 2008;9:691–701 https://doi.org/10.2340/
16501977-0265.
12. Jorge RE, Robinson RG, Moser D, et al. Major depression following traumatic
brain injury. Arch Gen Psychiatry. 2004;61:42–50.
13. Medley AR, Powell T. Motivational interviewing to promote self-awareness
and engagement in rehabilitation following acquired brain injury: A
conceptual review. Neuropsychol Rehabil. 2010;20:481–508 https://doi.org/
10.1080/09602011093529610.
14. Whelan-Goodinson R, Ponsford JL, Johnston L, et al. Psychiatric disorders
following traumatic brain injury: Their nature and frequency. J Head Trauma
Rehabil. 2009;24:324–32. https://doi.org/10.1097/HTR.0b013e3181a712aa.
15. Fann JR, Hart T, Schomer KG. Treatment for depression after traumatic brain
injury: A systematic review. J Neurotram. 2009;26:2383–402.
16. Verdelho A, Henon H, Lebert F, et al. Depressive symptoms after stroke and
relationship with dementia: A three year follow-up study. Neurology. 2004;
62:905–11.
17. Chemerinski E, Robinson RG, Kosier JT. Improved recovery of activities of
daily living associated with remission of poststroke depression. Stroke. 2001;
32:113–7.
18. House A, Knapp P, Bamford J, et al. Mortality at 12 and 24 months after
stroke may be associated with depressive symptoms at 1 month. Stroke.
2001;32:696–701.
19. Fazel S, Wolf A, Pillas D, et al. Suicide, fatal injuries, and other causes of
premature mortality in patients with traumatic brain injury. JAMA Psychiat.
2014;71:326–33 https://doi.org/10.1001/jamapsychiatry.2013.3935.
20. Waldron B, Casserly LM, O’Sullivan C. Cognitive behavioural therapy for
depression and anxiety in adults with acquired brain injury: What works for
whom? Neuropsychol Rehabil. 2013;23:64–101 https://doi.org/10.1080/
09602011.2012.724196.
21. MacLeod AK, Byrne A. Anxiety, depression, and the anticipation of future
positive and negative experiences. J Abnorm Psychol. 1996;105:286–9.
22. Morina N, Deeprose C, Pusowski C, et al. Prospective mental imagery in
patients with major depressive disorder or anxiety disorder. J Anxiety
Disord. 2011;25:1032–7.
23. Murphy FC, Peers PV, Blackwell SE, et al. Anticipated and imagined futures:
Prospective cognition and depressed mood following brain injury. Brit J Clin
Psychol. 2019;58:91–109 https://doi.org/10.1111/bjc.12202.
24. Kanter JW, Manos RC, Bowe WM, et al. What is behavioural activation? A
review of the empirical literature. Clin Psychol Rev. 2010;30:608–20 https://
doi.org/10.1016/j.cpr.2010.04.001.
25. Mazzucchelli T, Kane R, Rees CS. Behavioral activation treatments for
depression in adults: A meta-analysis and review. Clin Psychol-Sci Pr. 2009;
16:383–411 https://doi.org/10.1111/j.1468-2850.2009.01178.x.
26. Dimidjian s HSD, Dobson KS, et al. Randomized trial of behavioural
activation, cognitive therapy, and antidepressant medication in the acute
treatment of adults with major depression. J Consult Clin Psychol. 2006;74:
658–70 https://doi.org/10.1037/0022-006X.74.4.658.
27. Richards DA, Ekers D, McMillan D, et al. Cost and outcome of behavioural
activation versus cognitive behavioural therapy for depression (COBRA): A
randomised, controlled, non-inferiority trial. Lancet. 2016;388:871–80 https://
doi.org/10.1016/S0140-6736(16)31140-0.
28. Landreville P, Desrosiers J, Vincent C, et al. The role of activity restriction in
poststroke depressive symptoms. Rehabil Psychol. 2009;54:315–22.
29. Larsson J, Bjorkdahl A, Esbjornsson E, et al. Factors affecting participation
after traumatic brain injury. J Rehabil Med. 2013;45:765–70.
30. Mausbach BT, Chattillion EA, Moore RC, et al. Activity restriction and
depression in medical patients and their caregivers: A meta-analysis. Clin
Psychol Rev. 2011;31:900–8.
31. Oddy M, da Silva Ramos S, Fortescue D. Brain injury and social exclusion. In:
Bonner A, ed. Social Determinants of Health: An Interdisciplinary Approach
to Social Inequality and Wellbeing. Bristol: Policy Press; 2018:255 – 264.
32. Tate R, Wakim D, Genders M. A systematic review of the efficacy of
community-based, leisure/social activity programmes for people with
traumatic brain injury. Brain Impair. 2014;15:157–76.
33. Thomas SA, Walker MF, Macniven JA, et al. Communication and Low Mood
(CALM): A randomized controlled trial of behavioural therapy for stroke
patients with aphasia. Clin Rehabil. 2013;27:398–408.
34. Thomas SA, Coates E, das Nair R, et al. Behavioural Activation Therapy for
Depression after Stroke (BEADS): A study protocol for a feasibility
randomised controlled pilot trial of a psychological intervention for post-
stroke depression. Pilot Feasibility Stud. 2016;2:45 https://doi.org/10.1186/
s40814-016-0072-0.
35. Bombardier CH, Fann JR, Ludman EJ, et al. The relations of cognitive,
behavioral, and physical activity variables to depression severity in traumatic
brain injury: reanalysis of data from a randomized controlled trial. J Head
Trauma Rehabil. 2017;32:343–53. https://doi.org/10.1097/HTR.
0000000000000288.
36. Morris R, Morris P. Participants’ experiences of hospital-based peer support
groups for stroke patients and carers. Disabil Rehabil. 2012;34:347–54.
https://doi.org/10.3109/09638288.2011.607215.
37. Cuijpers P, van Straten A, Warmerdam L. Behavioral activation treatments of
depression: A meta-analysis. Clin Psychol Rev. 2007;27:318–26 https://doi.
org/10.1016/j.cpr.2006.11.001.
38. Ekers D, Richards D, Gilbody S. A meta-analysis of randomized trials of
behavioural treatment of depression. Psychol Med. 2008;38:611–23 https://
doi.org/10.1017/S0033291707001614.
39. Tucker M, Oei TPS. Is group more cost effective than individual cognitive
behaviour therapy? The evidence is not solid yet. Behav Cogn Psychother.
2007;35:77–91 https://doi.org/10.1017/S1352465806003134.
40. Lewinsohn P, Clarke G. Psychosocial treatment for adolescent depression.
Clin Psychol Rev. 1999;19:329–42.
41. Morrison N. Group cognitive therapy: Treatment of choice or sub-optimal
option? Behav Cogn Psychother. 2001;29:311–32.
42. Vinogradov S, Yalom I. Group therapy. In: Hales R, Yudofsky S, Talbott J,
editors. The American Psychiatric Press Textbook of Psychiatry. 2nd ed.
Washington: American Psychiatric press; 1994. p. 337–42.
43. Zigmond AS, Snaith RP. The Hospital and Anxiety and Depression Scale.
Acta Psychiatr Scand. 1983;67:361–70.
44. Lewinsohn PM. A behavioural approach to depression. In: Friedman RJ, Katz
MM, editors. The Psychology of Depression: Contemporary Theory and
Research. Washington, DC: Winston-Wiley Press; 1976. p. 157–85.
45. Lewinsohn PM, Sullivan JM, Grosscap SJ. Changing reinforcing events: An
approach to the treatment of depression. Psychother-Theor Res. 1980;17:
322–34.
46. Levine B, Robertson IH, Clare L, et al. Rehabilitation of executive functioning:
An experimental-clinical validation of goal management training. J Int
Neuropsychol Soc. 2000;6:299–312.
47. Levine B, Schweizer TA, O’Connor C, et al. Rehabilitation of executive
functioning in patients with frontal lobe brain damage with goal
management training. Front Hum Neurosci. 2011;5:9.
48. Cicerone KD, Langenbahn DM, Braden C, et al. Evidence-based cognitive
rehabilitation: Updated review of the literature from 2003 to 2008. Arch
Phys Med Rehabil. 2011;92:519–30. https://doi.org/10.1016/j.apmr.2010.11.
015..
49. Kanter JW, Mulick PS, Busch AM, et al. The Behavioural Activation for
Depression Scale (BADS): Psychometric properties and factor structure. J
Psychopathol Behav. 2007;29:191–202 https://doi.org/10.1007/s10862-006-
9038-5.
Kusec et al. Pilot and Feasibility Studies           (2020) 6:135 Page 16 of 17
50. Peers PV, Astle DE, Duncan J, et al. Dissociable effects of attention vs
working memory training on cognitive performance and everyday
functioning following fronto-parietal strokes. Neuropsychol Rehabil. 2018;20:
1–23 https://doi.org/10.1080/09602011.2018.1554534.
51. Gracey F, Fish JE, Greenfield E, et al. A randomized controlled trial of
assisted intention monitoring for the rehabilitation of executive
impairments following acquired brain injury. Neurorehabil Neural Repair.
2017;31:323–33 https://doi.org/10.1177/1545968316680484.
52. Burgess PW, Alderman N, Wilson BA, et al. The dysexecutive questionnaire.
In: Behavioural assessment of the dysexecutive syndrome. Bury St Edmunds:
Thames Valley Test Company.
53. Simblett SK, Ring H, Bateman A. The Dysexecutive Questionnaire Revised
(DEX-R): An extended measure of everyday dysexecutive problems after
acquired brain injury. Neuropsychol Rehabil. 2017;27:1124–41. https://doi.
org/10.1080/09602011.2015.1121880.
54. Teasdale TW, Christensen AL, Willmes K, et al. Subjective experience in brain
injured patients and their close relatives: A European Brain Injury
Questionnaire study. Brain Inj. 1997;11:543–64.
55. Kanter JW, Rusch LC, Busch AM, et al. Validation of the Behavioral Activation
for Depression Scale (BADS) in a community sample with elevated
depressive symptoms. J Psychopathol Behav. 2009;31:36–42 https://doi.org/
10.1007/s10862-008-9088-y.
56. Dawkins N, Cloherty ME, Gracey F, et al. The factor structure of the Hospital
Anxiety and Depression Scale in acquired brain injury. Brain Inj. 2006;20:
1235–9 https://doi.org/10.1080/02699050601076414.
57. Schönberger M, Ponsford J. The factor structure of the Hospital Anxiety and
Depression Scale in individuals with traumatic brain injury. Psychiatry Res.
2010;179:342–9 https://doi.org/10.1016/j.psychres.2009.07.003.
58. Dahm J, Wong D, Ponsford J. Validity of the Depression Anxiety Stress
Scales in assessing depression and anxiety following traumatic brain injury.
J Affect Disord. 2013;151:392–6 https://doi.org/10.1016/j.jad.2013.06.011.
59. Whelan-Goodinson R, Ponsford J, Schönberger M. Validity of the Hospital
Anxiety and Depression Scale to assess depression and anxiety following
traumatic brain injury as compared with the Structured Clinical Interview for
DSM-IV. J Affect Disord. 2009;114:94–102 https://doi.org/10.1016/j.jad.2008.
06.007.
60. Carver CS, White TL. Behavioral inhibition, behavioural activation, and
affective responses to impending reward and punishment: The BIS/BAS
scales. J Pers Soc Psychol. 1994;67:319–33.
61. Carleton RN, Norton PJ, Asmundson GJG. Fearing the unknown: A short
version of the Intolerance of Uncertainty Scale. J Anxiety Disord. 2007;21:
105–17. https://doi.org/10.1016/j.janxdis.2006.03.014.
62. McEvoy PM, Mahoney AE. Achieving certainty about the structure of
intolerance of uncertainty in a treatment-seeking sample with anxiety and
depression. J Anxiety Disord. 2011;25:112–22 https://doi.org/10.1016/j.
janxdis.2010.08.010.
63. Weiss DS. The Impact of Event Scale: Revised. In: Cross-cultural Assessment
of Psychological Trauma and PTSD. Boston: Springer; 2007. p. 219–38.
64. Sveen J, Low A, Dyster-Aas J, Ekselius L, et al. Validation of a Swedish
version of the Impact of Event Scale-Revised (IES-R) in patients with burns. J
Anxiety Disord. 2010;24:618–22 https://doi.org/10.1016/j.janxdis.2010.03.021.
65. Baumert J, Simon H, Gündel H, et al. The impact of event scale—revised:
evaluation of the subscales and correlations to psychophysiological startle
response patterns in survivors of a life-threatening cardiac event: an analysis
of 129 patients with an implanted cardioverter defibrillator. J Affect Disord.
2004;82:29–41 https://doi.org/10.1016/j.jad.2003.09.006.
66. Beck JG, Grant DM, Read JP, et al. The Impact of Event Scale-Revised:
Psychometric properties in a sample of motor vehicle accident survivors. J
Anxiety Disord. 2008;22(2):187–98.
67. Oddy M, Cattran C, Wood R. The development of a measure of motivational
changes following acquired brain injury. J Clin Exp Neuropsychol. 2008;30:
568–75 https://doi.org/10.1080/13803390701555598.
68. Kusec A, DeMatteo C, Velikonja D, et al. Psychometric properties of measures
of motivation and engagement after acquired brain injury. Rehabil Psychol.
2018;63:92–103 https://psycnet.apa.org/doi/10.1037/rep0000186.
69. Chervinsky AB, Ommaya AK, Spector J, et al. Motivation for traumatic brain
injury rehabilitation questionnaire (MOT-Q): reliability, factor analysis, and
relationship to MMPI-2 variables. Arch Clin Neuropsychol. 1998;13:433–46.
70. Brown M, Djikers MP, Gordon WA, et al. Participation objective, participation
subjective: A measure of participation combining outsider and insider
perspectives. J Head Trauma Rehabil. 2004;19:459–81.
71. Snaith RP, Hamilton M, Morley S, et al. A scale for the assessment of
hedonic tone: The Snaith-Hamilton Pleasure Scale. Brit J Psychiat. 1995;167:
99–103.
72. Franken IH, Rassin E, Muris P. The assessment of anhedonia in clinical and
non-clinical populations: further validation of the Snaith–Hamilton Pleasure
Scale (SHAPS). J Affect Disord. 2007;99:83–9 https://doi.org/10.1016/j.jad.
2006.08.020.
73. Nakonezny PA, Carmody TJ, Morris DW, et al. Psychometric evaluation of
the Snaith–Hamilton Pleasure Scale (SHAPS) in adult outpatients with major
depressive disorder. Int Clin Psychopharmacol. 2010;25:328–33. https://doi.
org/10.1097/YIC.0b013e32833eb5ee.
74. Lachman ME, Weaver SL. The sense of control as a moderator of social class
differences in health and well-being. J Pers Soc Psychol. 1998;74:763–73.
75. Lachman ME, Weaver SL. Sociodemographic variations in the sense of
control by domain: Findings from the MacArthur studies of midlife. Psychol
Aging. 1998;13:553–62 https://doi.org/10.1037/0882-7974.13.4.553.
76. Devilly GJ, Borkovec TD. Psychometric properties of the Credibility/
Expectancy Questionnaire. J Behav Ther Exp Psy. 2000;31:73–86.
77. R Core Team. R: A language and environment for statistical computing. R
Foundation for Statistical Computing. 2013. Vienna, Austria. URL http://
www.R-project.org/.
78. Sim J. Should treatment effects be estimated in pilot and feasibility studies?
Pilot Feasibility Stud. 2019;5:107. https://doi.org/10.1186/s40814-019-0493-7.
79. Thorne S, Kirkham SR, O’Flynn-Magee K. The analytic challenge in
interpretive description. Int J Qual Methods. 2004;3:1–11.
80. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol.
2006;3:77–101.
81. Bombardier CH, Fann JR, Temkin NR, et al. Rates of major depressive
disorder and clinical outcomes following traumatic brain injury. JAMA. 2010;
303:1938–45.
82. Hackett ML, Yapa C, Parag V, Anderson CS. Frequency of depression after
stroke: A systematic review of observational studies. Stroke. 2005;36:1330–
40.
83. Egan M, Davis CG, Dubouloz CJ, et al. Participation and well-being
poststroke: Evidence of reciprocal effects. Arch Phys Med Rehabil. 2014;95:
262–8 https://doi.org/10.1016/j.apmr.2013.08.013.
84. Fleming J, Nalder E, Alves-Stein S, et al. The effect of environmental barriers
on community integration for individuals with moderate to severe
traumatic brain injury. J Head Trauma Rehabil. 2014;29:125–35. https://doi.
org/10.1097/HTR.0b013e318286545d.
85. Wise EK, Mathews-Dalton C, Dikmen S, et al. Impact of traumatic brain
injury on participation in leisure activities. Arch Phys Med Rehabil. 2010;91:
1357–62. https://doi.org/10.1016/j.apmr.2010.06.009.
86. Ekers D, Richards D, McMillan D, et al. Behavioural activation delivered by
the non-specialist: phase II randomised controlled trial. Brit J Psychiat. 2011;
198:66–72 https://doi.org/10.1192/bjp.bp.110.079111.
87. Penfield W, Milner B. Memory deficit produced by bilateral lesions in the
hippocampal zone. AMA Arch Neurol Psy. 1958;79:475–97.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Kusec et al. Pilot and Feasibility Studies           (2020) 6:135 Page 17 of 17
